|
1
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: Multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reiss K and Saftig P: The 'a disintegrin
and metalloprotease' (ADAM) family of sheddases: Physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
View Article : Google Scholar
|
|
3
|
White JM: ADAMs: Modulators of cell-cell
and cell-matrix interactions. Curr Opin Cell Biol. 15:598–606.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duffy MJ, Mullooly M, O'Donovan N, Sukor
S, Crown J, Pierce A and McGowan PM: The ADAMs family of proteases:
New biomarkers and therapeutic targets for cancer? Clin Proteomics.
8:92011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klessner JL, Desai BV, Amargo EV, Getsios
S and Green KJ: EGFR and ADAMs cooperate to regulate shedding and
endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol
Biol Cell. 20:328–337. 2009. View Article : Google Scholar :
|
|
6
|
Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E,
Higuchi S, Suzuki H, Nakashima H, Eguchi K and Eguchi S: ADAM17
mediates epidermal growth factor receptor transactivation and
vascular smooth muscle cell hypertrophy induced by angiotensin II.
Arterioscler Thromb Vasc Biol. 26:e133–e137. 2006.PubMed/NCBI
|
|
7
|
Higashiyama S and Nanba D: ADAM-mediated
ectodomain shedding of HB-EGF in receptor cross-talk. Biochim
Biophys Acta. 1751:110–117. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maretzky T, Reiss K, Ludwig A, Buchholz J,
Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10
mediates E-cadherin shedding and regulates epithelial cell-cell
adhesion, migration, and beta-catenin translocation. Proc Natl Acad
Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Najy AJ, Day KC and Day ML: The ectodomain
shedding of E-cadherin by ADAM15 supports ErbB receptor activation.
J Biol Chem. 283:18393–18401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kohutek ZA, diPierro CG, Redpath GT and
Hussaini IM: ADAM-10-mediated N-cadherin cleavage is protein kinase
C-alpha dependent and promotes glioblastoma cell migration. J
Neurosci. 29:4605–4615. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krätzschmar J, Lum L and Blobel CP:
Metargidin, a membrane-anchored metalloprotease-disintegrin protein
with an RGD integrin binding sequence. J Biol Chem. 271:4593–4596.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nath D, Slocombe PM, Stephens PE, Warn A,
Hutchinson GR, Yamada KM, Docherty AJ and Murphy G: Interaction of
metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on
different haemopoietic cells. J Cell Sci. 112:579–587.
1999.PubMed/NCBI
|
|
14
|
Kuefer R, Day KC, Kleer CG, Sabel MS,
Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA and Day
ML: ADAM15 disintegrin is associated with aggressive prostate and
breast cancer disease. Neoplasia. 8:319–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carl-McGrath S, Lendeckel U, Ebert M,
Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9,
ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol.
26:17–24. 2005.
|
|
16
|
Ortiz RM, Kärkkäinen I and Huovila AP:
Aberrant alternative exon use and increased copy number of human
metalloprotease-disintegrin ADAM15 gene in breast cancer cells.
Genes Chromosomes Cancer. 41:366–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Najy AJ, Day KC and Day ML: ADAM15
supports prostate cancer metastasis by modulating tumor
cell-endothelial cell interaction. Cancer Res. 68:1092–1099. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toquet C, Colson A, Jarry A, Bezieau S,
Volteau C, Boisseau P, Merlin D, Laboisse CL and Mosnier JF: ADAM15
to α5β1 integrin switch in colon carcinoma cells: A late event in
cancer progression associated with tumor dedifferentiation and poor
prognosis. Int J Cancer. 130:278–287. 2012. View Article : Google Scholar
|
|
19
|
Carney DN: Lung cancer - time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen WQ, Zhang SW, Zou XN and Zhao P: An
analysis of lung cancer mortality in China, 2004–2005. Zhonghua Yu
Fang Yi Xue Za Zhi. 44:378–382. 2010.In Chinese. PubMed/NCBI
|
|
22
|
Schütz A, Härtig W, Wobus M, Grosche J,
Wittekind Ch and Aust G: Expression of ADAM15 in lung carcinomas.
Virchows Arch. 446:421–429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou H, Chen JH, Hu J, Luo YZ, Li F, Xiao
L and Zhong MZ: High expression of Toll-like receptor 5 correlates
with better prognosis in non-small-cell lung cancer: An anti-tumor
effect of TLR5 signaling in non-small cell lung cancer. J Cancer
Res Clin Oncol. 140:633–643. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian
X, Aggarwal BB and Liu M: Acetyl-11-keto-beta-boswellic acid
inhibits prostate tumor growth by suppressing vascular endothelial
growth factor receptor 2-mediated angiogenesis. Cancer Res.
69:5893–5900. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cox G, Jones JL and O'Byrne KJ: Matrix
metalloproteinase 9 and the epidermal growth factor signal pathway
in operable non-small cell lung cancer. Clin Cancer Res.
6:2349–2355. 2000.PubMed/NCBI
|
|
27
|
Cheng CY, Hsieh HL, Hsiao LD and Yang CM:
PI3-K/Akt/JNK/NF-κB is essential for MMP9 expression and outgrowth
in human limbal epithelial cells on intact amniotic membrane. Stem
Cell Res. 9:9–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albrechtsen R, Kveiborg M, Stautz D, et
al: ADAM12 redistributes and activates MMP-14, resulting in gelatin
degradation, reduced apoptosis and increased tumor growth. J Cell
Sci. 126:4707–4720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiao LJ, Lin P, Lin F, et al: ADAM17
targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to
promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724.
2012.
|
|
31
|
Sato H, Kida Y, Mai M, Endo Y, Sasaki T,
Tanaka J and Seiki M: Expression of genes encoding type IV
collagen-degrading metalloproteinases and tissue inhibitors of
metalloproteinases in various human tumor cells. Oncogene. 7:77–83.
1992.PubMed/NCBI
|
|
32
|
Kim S, Choi JH, Lim HI, Lee SK, Kim WW,
Cho S, Kim JS, Kim JH, Choe JH, Nam SJ, et al: EGF-induced MMP9
expression is mediated by the JAK3/ERK pathway, but not by the
JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell
Signal. 21:892–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
O-Charoenrat P, Rhys-Evans P, Modjtahedi
H, Court W, Box G and Eccles S: Overexpression of epidermal growth
factor receptor in human head and neck squamous carcinoma cell
lines correlates with matrix metalloproteinase-9 expression and in
vitro invasion. Int J Cancer. 86:307–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
